U
HAE icon

UBS’s Haemonetics HAE Stock Holding History

UBS’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$96K Sell
2,756
-1,064
-28% -$38K ﹤0.01% 6045
2014
Q2 		$135K Buy
3,820
+652
+21% +$21.8K ﹤0.01% 5599
2014
Q1 		$103K Sell
3,168
-3,324
-51% -$127K ﹤0.01% 5938
2013
Q4 		$273K Buy
6,492
+1,296
+25% +$53.3K ﹤0.01% 4953
2013
Q3 		$207K Buy
5,196
+1,437
+38% +$60.3K ﹤0.01% 5135
2013
Q2 		$155K Buy
+3,759
New +$152K ﹤0.01% 5377

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.7B AUM 21.48% 1-Year Est. Return

UBS's HAE Position: Q3 2014 in Review

UBS reduced its Haemonetics (HAE) stake by 28% in Q3 2014, selling an estimated $38K and leaving 2,756 shares worth $96K. The position accounts for ﹤0.01% of the portfolio, ranked #6045.

UBS first reported a position in HAE in Q2 2013 and has held it in 6 quarters since. The position peaked at $273K in Q4 2013. 171 funds tracked by Wall St. Rank hold HAE as of Q3 2014.

  • UBS held 2,756 shares of Haemonetics worth $96K as of Q3 2014.
  • UBS sold 1,064 Haemonetics shares in Q3 2014, an estimated $38K.
  • Haemonetics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6045 holding.
  • UBS first reported a position in Haemonetics in Q2 2013 and has held it in 6 quarters since.
  • UBS's Haemonetics position peaked at $273K in Q4 2013.
  • 171 funds tracked by Wall St. Rank held Haemonetics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.